Imatinib may reduce chemotherapy-induced pneumonitis. A report on four cases from the SWENOTECA

Acta Oncol. 2018 Oct;57(10):1401-1406. doi: 10.1080/0284186X.2018.1479072. Epub 2018 Jun 5.


Background: An increasing number of anticancer drugs have been reported to cause pneumonitis. Chemotherapy-induced pneumonitis may cause severe morbidity and event death. As there has been a lack of effective treatment, new treatment strategies are needed. A previous case report has indicated that imatinib may be useful.

Patient and methods: The SWENOTECA experience of four cases with severe life-threatening chemotherapy-induced pneumonitis treated with imatinib is presented.

Results: All four patients responded to treatment with imatinib.

Conclusions: Imatinib appears to be an effective treatment of severe chemotherapy-induced pneumonitis in germ cell cancer patients.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents / adverse effects*
  • Humans
  • Imatinib Mesylate / therapeutic use*
  • Male
  • Middle Aged
  • Pneumonia / chemically induced
  • Pneumonia / prevention & control*


  • Antineoplastic Agents
  • Imatinib Mesylate